A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC)

Brief description of study

The purpose of the study is to determine and evaluate the safety, tolerability, and systemic exposure of intravesical enfortumab vedotin. We want to identify the maximum tolerated dose or the recommended dose. As a result, we want to characterize the safety, pharmacokinetics, and antitumor activity of intravesical enfortumab vedotin.


Clinical Study Identifier: s21-00401
ClinicalTrials.gov Identifier: NCT05014139
Principal Investigator: Gary D. Steinberg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.